Only CBD products on the list are permitted by the FSA to stay on the market, in line with the UK’s Novel Food requirements. ACI shared that CBD products on the list have been undergoing assessment by the FSA in a "long and rigorous" Novel Food process that was open to any CBD product designed for oral consumption that was on sale in the UK on or before February 12, 2020, with the deadline for applications set at March 31, 2021. Any product launched after the February date, or which was not the subject of a dossier submitted by the cut-off date, may not now be sold until full authorization is granted. Products not on the list must be removed from shelves.
“The FSA public list represents a major milestone for the UK’s CBD category," said Steve Moore, ACI Founder. "It demonstrates the progress the sector has made to meet compliance requirements and creates greater regulatory certainty which, in turn, will increase levels of consumer trust, encourage investment in the sector, and promote innovation. ACI is immensely grateful for the work that our members and the FSA have put in to take this momentous step.”
ACI also shared that it is working with Trading Standards to enforce the new rules, with any company offering unlisted CBD products for sale facing possible action by its officers. The FSA list covers products sold in England and Wales. Products designed to be inhaled or applied to the skin do not fall under the FSA’s remit. Businesses selling CBD products for human consumption are urged to check their stock against the list to ensure they are compliant. ACI has launchedwww.UKCBDList.comto serve as a reference point for consumers, retailers, health practitioners, and enforcement authorities to verify whether a product is being sold legally.
